New Treatment for Multiple Sclerosis Shows Promise in Small Trial

Researchers today announced progress toward a multiple sclerosis treatment that fights myelin destruction while keeping patients’ immune systems intact. The research, a result of a phase 1 clinical trial, is the latest attempt to improve on current MS therapies. MS is believed to turn the body’s immune system against itself to destroy the nerve-insulating myelin, disrupting how signals travel from the brain and spinal cord. Current treatments thus suppress the overactive immune system---but in the process they leave the patient more vulnerable to infection and relapses of symptoms. The treatment approach in trials now instead "retrains" patients' immune systems to tolerate myelin. Previous studies in mice have shown that delivering pieces of the myelin protein to the bloodstream can desensitize the immune system to myelin and slow degeneration. Today, in the first human study of the approach, researchers in Germany, Switzerland and Chicago report similar promise in people. Researchers took ...